BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 30888999)

  • 21. Can
    Peng L; Li J; Meng C; Li J; You C; Tang D; Wei T; Xiong W; Li Y
    Radiat Oncol; 2020 Oct; 15(1):227. PubMed ID: 33004037
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
    World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
    Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
    Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.
    Fendler WP; Schmidt DF; Wenter V; Thierfelder KM; Zach C; Stief C; Bartenstein P; Kirchner T; Gildehaus FJ; Gratzke C; Faber C
    J Nucl Med; 2016 Nov; 57(11):1720-1725. PubMed ID: 27261520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of
    Bailey J; Piert M
    Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of
    Liu X; Wang Q; Zhang B; Jiang T; Zeng W
    Hell J Nucl Med; 2022; 25(1):88-102. PubMed ID: 35388806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis.
    Guo Y; Wang L; Hu J; Feng D; Xu L
    PLoS One; 2018; 13(9):e0203400. PubMed ID: 30192819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison Between
    Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
    Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Wang R; Shen G; Yang R; Ma X; Tian R
    Eur J Radiol; 2020 Sep; 130():109131. PubMed ID: 32622250
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Zhou J; Wu R; Wang W; Zhao Y; Liu X
    Hell J Nucl Med; 2022; 25(3):297-311. PubMed ID: 36576728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of PSMA imaging in prostate cancer].
    Gasch C; Düwel C; Kopka K; Kratochwil C; Vinsensia M; Eiber M; Maurer T; Haberkorn U; Hadaschik B; Giesel FL
    Urologe A; 2017 Jan; 56(1):3-12. PubMed ID: 28005153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frusemide aids diagnostic interpretation of
    Fennessy N; Lee J; Shin J; Ho B; Ali SA; Paschkewitz R; Emmett L
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.
    Umbehr MH; Müntener M; Hany T; Sulser T; Bachmann LM
    Eur Urol; 2013 Jul; 64(1):106-17. PubMed ID: 23628493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.